You are here

Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R42AI136065-01A1
Agency Tracking Number: R42AI136065
Amount: $297,455.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA17-303
Timeline
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-02-05
Award End Date (Contract End Date): 2019-01-31
Small Business Information
2 DAVIS DR
Research Triangle Park, NC 27709-0003
United States
DUNS: 080059821
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 CARL KRAUS
 (347) 334-2687
 ckraus@arrevus.com
Business Contact
 ROBERT HOUSE
Phone: (347) 334-2687
Email: rhouse@arrevus.com
Research Institution
 LA BIOMED RES INST/ HARBOR UCLA MED CTR
 
1124 WEST CARSON ST
TORRANCE, CA 90502-2006
United States

 Domestic nonprofit research organization
Abstract

Bloodstream infectionsBSIscaused by Gram negative bacterial pathogens are associated with significant
morbidity and mortality due to the antibiotic resistant nature of the pathogensInfections caused by multi drug
resistantMDRbacterial pathogens result in substantial health and economic impact due to the lack of
effective therapeutic optionsThis lack of treatment options is particularly relevant for MDR Gram negative
pathogenssuch as Pseudomonas aeruginosa and Acinetobacter baumanniiwhich have shown a great
propensity to challenge the clinical care of patients suffering from such infectionsArrevus is developing a
novel approach to addressing Gram negative MDR infections through the use of Designer Proline rich
Antimicrobial peptide Chaperone protein inhibitorsDPCsderived from insectswhich serve as inhibitors to
one of the critical bacterial proteins responsible for bacterial protein foldingDnaKAs an adjuvant therapy to
current antibioticsDPCs have the potential to provide a much improved treatment option for MDR Gramnegative bacterial infectionsPreliminary studies have displayed the potential of ARVthe lead DPCas an antibiotic potentiating agent
against MDR Gram negative bacterial pathogensOur efforts have shown thatARVvia an
intramuscular route is effective against MDR Abaumannii in a bacteremia modelARVenhances the
activity of colistin and imipenemARVhas a favorable preliminary safety profileandARVenhances the effects of legacy antimicrobials through a novel mechanism of actionCollectivelythese data
support the continued development of AVRthrough a Fast Track program that is geared toward
characterizing the therapeutic potential and safety profile of ARVin order to construct a target product
profileTPPThis overall goal will be met through the execution of the following aimsPhase I Specific Aims areTo define the spectrum of activity of ARVTo evaluate the efficacy
of intravenous dosing of ARVfor the treatment of Gram negative BSIsThe measures of success to
advance to Phase II areIdentification of an optimal antibiotic for use as a co treatment with ARVagainst Gram negative pathogensandDetermination of the efficacy of ARVwhen delivered
intravenously in a Gram negative BSI mouse modelPhase II Specific Aims areTo characterize the pharmacological properties and therapeutic activity
of ARVTo obtain a preliminary safety profile of ARVThe measure of success for Phase II
is to complete key pharmacological and safety assessments to craft the TPP The prevalence of Gram negative bloodstream infections is in the riseand these infections are increasingly
difficult to treat with existing antibiotics due to antibiotic resistanceArrevus is developing a new class
antimicrobial peptides derived from insects that act via a novel mode of action to enhance the ability of
antibiotics to treat infections caused by Gram negative antibiotic resistant bacteria

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government